The association between the presence and burden of periodic discharges and outcome in septic patients: an observational prospective study.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
09 05 2023
Historique:
received: 24 02 2023
accepted: 04 05 2023
medline: 11 5 2023
pubmed: 10 5 2023
entrez: 10 5 2023
Statut: epublish

Résumé

Sepsis-associated encephalopathy (SAE) is frequent in septic patients. Electroencephalography (EEG) is very sensitive to detect early epileptic abnormalities, such as seizures and periodic discharges (PDs), and to quantify their duration (the so-called burden). However, the prevalence of these EEG abnormalities in septic patients, as well as their effect on morbidity and mortality, are still unclear. The aims of this study were to assess whether the presence of electrographic abnormalities (i.e. the absence of reactivity, the presence and burden of seizures and PDs) was associated with functional outcome and mortality in septic patients and whether these abnormalities were associated with sepsis-associated encephalopathy (SAE). We prospectively included septic patients, without known chronic or acute intracranial disease or pre-existing acute encephalopathy, requiring ICU admission in a tertiary academic centre. Continuous EEG monitoring was started within 72 h after inclusion and performed for up to 7 days. A comprehensive assessment of consciousness and delirium was performed twice daily by a trained neuropsychologist. Primary endpoints were unfavourable functional outcome (UO, defined as a Glasgow Outcome Scale-Extended-GOSE-score < 5), and mortality collected at hospital discharge and secondary endpoint was the association of PDs with SAE. Mann-Whitney, Fisher's exact and χ We included 92 patients. No seizures were identified. Nearly 25% of patients had PDs. The presence of PDs and PDs burden was associated with UO in univariate (n = 15 [41%], p = 0.005 and p = 0.008, respectively) and, for PDs presence, also in multivariate analysis after correcting for disease severity (OR 3.82, IC 95% [1.27-11.49], p = 0.02). The PDs burden negatively correlated with GOSE (Spearman's coefficient ρ = - 0.2, p = 0.047). The presence of PDs was also independently associated with SAE (OR 8.98 [1.11-72.8], p = 0.04). Reactivity was observed in the majority of patients and was associated with outcomes (p = 0.044 for both functional outcome and mortality). Our findings suggest that PDs and PDs burden are associated with SAE and might affect outcome in septic patients.

Sections du résumé

BACKGROUND
Sepsis-associated encephalopathy (SAE) is frequent in septic patients. Electroencephalography (EEG) is very sensitive to detect early epileptic abnormalities, such as seizures and periodic discharges (PDs), and to quantify their duration (the so-called burden). However, the prevalence of these EEG abnormalities in septic patients, as well as their effect on morbidity and mortality, are still unclear. The aims of this study were to assess whether the presence of electrographic abnormalities (i.e. the absence of reactivity, the presence and burden of seizures and PDs) was associated with functional outcome and mortality in septic patients and whether these abnormalities were associated with sepsis-associated encephalopathy (SAE).
METHODS
We prospectively included septic patients, without known chronic or acute intracranial disease or pre-existing acute encephalopathy, requiring ICU admission in a tertiary academic centre. Continuous EEG monitoring was started within 72 h after inclusion and performed for up to 7 days. A comprehensive assessment of consciousness and delirium was performed twice daily by a trained neuropsychologist. Primary endpoints were unfavourable functional outcome (UO, defined as a Glasgow Outcome Scale-Extended-GOSE-score < 5), and mortality collected at hospital discharge and secondary endpoint was the association of PDs with SAE. Mann-Whitney, Fisher's exact and χ
RESULTS
We included 92 patients. No seizures were identified. Nearly 25% of patients had PDs. The presence of PDs and PDs burden was associated with UO in univariate (n = 15 [41%], p = 0.005 and p = 0.008, respectively) and, for PDs presence, also in multivariate analysis after correcting for disease severity (OR 3.82, IC 95% [1.27-11.49], p = 0.02). The PDs burden negatively correlated with GOSE (Spearman's coefficient ρ = - 0.2, p = 0.047). The presence of PDs was also independently associated with SAE (OR 8.98 [1.11-72.8], p = 0.04). Reactivity was observed in the majority of patients and was associated with outcomes (p = 0.044 for both functional outcome and mortality).
CONCLUSION
Our findings suggest that PDs and PDs burden are associated with SAE and might affect outcome in septic patients.

Identifiants

pubmed: 37161485
doi: 10.1186/s13054-023-04475-w
pii: 10.1186/s13054-023-04475-w
pmc: PMC10170680
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

179

Informations de copyright

© 2023. The Author(s).

Références

Int J Environ Res Public Health. 2020 Aug 12;17(16):
pubmed: 32806705
Crit Care. 2013 Sep 18;17(5):R204
pubmed: 24047502
JAMA. 2004 Apr 14;291(14):1753-62
pubmed: 15082703
PLoS One. 2015 Oct 08;10(10):e0139969
pubmed: 26447697
Crit Care. 2007;11(2):R31
pubmed: 17331245
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
J Clin Neurophysiol. 1992 Jan;9(1):145-52
pubmed: 1552002
Neurobiol Dis. 2014 Dec;72 Pt B:193-7
pubmed: 25224522
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Crit Care Med. 1990 Aug;18(8):801-6
pubmed: 2379391
Nat Rev Neurol. 2012 Oct;8(10):557-66
pubmed: 22986430
JAMA. 2010 Oct 27;304(16):1787-94
pubmed: 20978258
Neurology. 2012 Nov 6;79(19):1951-60
pubmed: 23035068
Clin Invest Med. 1990 Dec;13(6):297-304
pubmed: 2078909
J Clin Neurophysiol. 2013 Jun;30(3):247-54
pubmed: 23733088
J Clin Neurophysiol. 2013 Feb;30(1):1-27
pubmed: 23377439
Chin Med J (Engl). 2012 Mar;125(5):828-31
pubmed: 22490582
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Brain. 2014 May;137(Pt 5):1429-38
pubmed: 24595203
Crit Care Med. 2009 Jun;37(6):2051-6
pubmed: 19384197
J Neurotrauma. 1998 Aug;15(8):573-85
pubmed: 9726257
Intensive Care Med. 2014 Feb;40(2):228-234
pubmed: 24240843
Neurocrit Care. 2020 Feb;32(1):121-130
pubmed: 30891696
Clinics (Sao Paulo). 2011;66(10):1825-31
pubmed: 22012058
Crit Care Med. 2001 Jul;29(7):1370-9
pubmed: 11445689
Neurology. 2016 Jan 19;86(3):253-60
pubmed: 26701381
Intensive Care Med Exp. 2020 Aug 14;8(1):44
pubmed: 32797301
Intensive Care Med. 2015 Apr;41(4):686-94
pubmed: 25763756
JAMA. 2003 Jun 11;289(22):2983-91
pubmed: 12799407
Arch Phys Med Rehabil. 2004 Dec;85(12):2020-9
pubmed: 15605342
J Clin Neurophysiol. 2021 Jan 1;38(1):1-29
pubmed: 33475321
Crit Care. 2014 Dec 08;18(6):674
pubmed: 25482125

Auteurs

Lorenzo Ferlini (L)

Department of Neurology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070, Brussels, Belgium. lorenzo.ferlini@hubruxelles.be.

Christelle Maenhout (C)

Department of Neurology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070, Brussels, Belgium.

Ilaria Alice Crippa (IA)

Department of Anesthesiology and Intensive Care, Policlinico San Marco, Gruppo San Donato, Zingonia, Italy.
Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Armin Alvaro Quispe-Cornejo (AA)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Jacques Creteur (J)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Fabio Silvio Taccone (FS)

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Nicolas Gaspard (N)

Department of Neurology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070, Brussels, Belgium.
Department of Neurology, Yale University School of Medicine, New Haven, CT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH